Cargando…

Humoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants

Although both C-C chemokine receptor 5 (CCR5)- and CXC chemokine receptor 4 (CXCR4)-using HIV-1 strains cause AIDS, the emergence of CXCR4-utilizing variants is associated with an accelerated decline in CD4 + T cells. It remains uncertain if CXCR4-using viruses hasten disease or if these variants on...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Nina, Gonzalez, Oscar A., Registre, Ludy, Becerril, Carlos, Etemad, Behzad, Lu, Hong, Wu, Xueling, Lockman, Shahin, Essex, Myron, Moyo, Sikhulile, Kuritzkes, Daniel R., Sagar, Manish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4919596/
https://www.ncbi.nlm.nih.gov/pubmed/27428434
http://dx.doi.org/10.1016/j.ebiom.2016.04.040
_version_ 1782439273647046656
author Lin, Nina
Gonzalez, Oscar A.
Registre, Ludy
Becerril, Carlos
Etemad, Behzad
Lu, Hong
Wu, Xueling
Lockman, Shahin
Essex, Myron
Moyo, Sikhulile
Kuritzkes, Daniel R.
Sagar, Manish
author_facet Lin, Nina
Gonzalez, Oscar A.
Registre, Ludy
Becerril, Carlos
Etemad, Behzad
Lu, Hong
Wu, Xueling
Lockman, Shahin
Essex, Myron
Moyo, Sikhulile
Kuritzkes, Daniel R.
Sagar, Manish
author_sort Lin, Nina
collection PubMed
description Although both C-C chemokine receptor 5 (CCR5)- and CXC chemokine receptor 4 (CXCR4)-using HIV-1 strains cause AIDS, the emergence of CXCR4-utilizing variants is associated with an accelerated decline in CD4 + T cells. It remains uncertain if CXCR4-using viruses hasten disease or if these variants only emerge after profound immunological damage. We show that exclusively CXCR4- as compared to cocirculating CCR5-utilizing variants are less sensitive to neutralization by both contemporaneous autologous plasma and plasma pools from individuals that harbor only CCR5-using HIV-1. The CXCR4-utilizing variants, however, do not have a global antigenic change because they remain equivalently susceptible to antibodies that do not target coreceptor binding domains. Studies with envelope V3 loop directed antibodies and chimeric envelopes suggest that the neutralization susceptibility differences are potentially influenced by the V3 loop. In vitro passage of a neutralization sensitive CCR5-using virus in the presence of autologous plasma and activated CD4 + T cells led to the emergence of a CXCR4-utilizing virus in 1 of 3 cases. These results suggest that in some but not necessarily all HIV-1 infected individuals humoral immune pressure against the autologous virus selects for CXCR4-using variants, which potentially accelerates disease progression. Our observations have implications for using antibodies for HIV-1 immune therapy.
format Online
Article
Text
id pubmed-4919596
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-49195962016-06-30 Humoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants Lin, Nina Gonzalez, Oscar A. Registre, Ludy Becerril, Carlos Etemad, Behzad Lu, Hong Wu, Xueling Lockman, Shahin Essex, Myron Moyo, Sikhulile Kuritzkes, Daniel R. Sagar, Manish EBioMedicine Research Paper Although both C-C chemokine receptor 5 (CCR5)- and CXC chemokine receptor 4 (CXCR4)-using HIV-1 strains cause AIDS, the emergence of CXCR4-utilizing variants is associated with an accelerated decline in CD4 + T cells. It remains uncertain if CXCR4-using viruses hasten disease or if these variants only emerge after profound immunological damage. We show that exclusively CXCR4- as compared to cocirculating CCR5-utilizing variants are less sensitive to neutralization by both contemporaneous autologous plasma and plasma pools from individuals that harbor only CCR5-using HIV-1. The CXCR4-utilizing variants, however, do not have a global antigenic change because they remain equivalently susceptible to antibodies that do not target coreceptor binding domains. Studies with envelope V3 loop directed antibodies and chimeric envelopes suggest that the neutralization susceptibility differences are potentially influenced by the V3 loop. In vitro passage of a neutralization sensitive CCR5-using virus in the presence of autologous plasma and activated CD4 + T cells led to the emergence of a CXCR4-utilizing virus in 1 of 3 cases. These results suggest that in some but not necessarily all HIV-1 infected individuals humoral immune pressure against the autologous virus selects for CXCR4-using variants, which potentially accelerates disease progression. Our observations have implications for using antibodies for HIV-1 immune therapy. Elsevier 2016-05-05 /pmc/articles/PMC4919596/ /pubmed/27428434 http://dx.doi.org/10.1016/j.ebiom.2016.04.040 Text en © 2016 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Paper
Lin, Nina
Gonzalez, Oscar A.
Registre, Ludy
Becerril, Carlos
Etemad, Behzad
Lu, Hong
Wu, Xueling
Lockman, Shahin
Essex, Myron
Moyo, Sikhulile
Kuritzkes, Daniel R.
Sagar, Manish
Humoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants
title Humoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants
title_full Humoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants
title_fullStr Humoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants
title_full_unstemmed Humoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants
title_short Humoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants
title_sort humoral immune pressure selects for hiv-1 cxc-chemokine receptor 4-using variants
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4919596/
https://www.ncbi.nlm.nih.gov/pubmed/27428434
http://dx.doi.org/10.1016/j.ebiom.2016.04.040
work_keys_str_mv AT linnina humoralimmunepressureselectsforhiv1cxcchemokinereceptor4usingvariants
AT gonzalezoscara humoralimmunepressureselectsforhiv1cxcchemokinereceptor4usingvariants
AT registreludy humoralimmunepressureselectsforhiv1cxcchemokinereceptor4usingvariants
AT becerrilcarlos humoralimmunepressureselectsforhiv1cxcchemokinereceptor4usingvariants
AT etemadbehzad humoralimmunepressureselectsforhiv1cxcchemokinereceptor4usingvariants
AT luhong humoralimmunepressureselectsforhiv1cxcchemokinereceptor4usingvariants
AT wuxueling humoralimmunepressureselectsforhiv1cxcchemokinereceptor4usingvariants
AT lockmanshahin humoralimmunepressureselectsforhiv1cxcchemokinereceptor4usingvariants
AT essexmyron humoralimmunepressureselectsforhiv1cxcchemokinereceptor4usingvariants
AT moyosikhulile humoralimmunepressureselectsforhiv1cxcchemokinereceptor4usingvariants
AT kuritzkesdanielr humoralimmunepressureselectsforhiv1cxcchemokinereceptor4usingvariants
AT sagarmanish humoralimmunepressureselectsforhiv1cxcchemokinereceptor4usingvariants